Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT trial of low-dose versus standard-dose ticagrelor in medically managed acute coronary syndrome
ChiCTR1900024375Phase 4Recruiting
- Sponsor
- Fuwai Central China Cardiovascular Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Fuwai Central China Cardiovascular Hospital. Primary endpoint: Platelet aggregation rate. Started Jul 2019; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR1900024375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024375.